Aggarwal, B
*Correspondence: Ricardo Tavares Pinheiro, [email protected] This article was submitted to Mood Disorders, a section of the journal Frontiers in Psychiatry Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The honest picture on human evidence: in February 2026, Hudson Biotech began recruiting for the first properly designed randomised controlled trial of BPC-157 in humans a Phase 2 trial that the research community has been waiting three decades for
Liposomal glutathione is glutathione encased in liposomes, which improves absorption and bioavailability
Figure 2: Categorical weight loss of either 5%, 10%, or 15% in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo